SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of iCAD, Inc. – ICAD

NEW YORK, NY / ACCESSWIRE / May 7, 2015 / Pomerantz LLP is investigating claims on behalf of investors of iCAD, Inc. (“iCAD” or the “Company”) (NASDAQ: ICAD). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.

The investigation concerns whether iCAD and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. 

On May 6, 2015, the Company announced that announced “that Noridian, the Medicare Administrative Contractor in Jurisdictions E and F, which consists of 13 states primarily on the West Coast, has made recent web postings related to Coding for High Dose Rate Brachytherapy for Non-Melanoma Skin Cancers which instruct physicians to report CPT code (17999) rather than the established CPT code (0182T) for electronic brachytherapy for non-melanoma skin cancers. The Company, industry partners and physician providers have reached out to the Centers for Medicare and Medicaid Services (“CMS”) and Noridian to seek clarification of the Medicare Coverage Articles posted to Noridian’s web sites.”

On this news, shares of iCAD fell $3.32 per share, to $4.63, or more than 41.76%, in intra-day trading on May 7, 2015.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 428647